Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Patent Round-Up: Sanofi Settles Eloxatin Suits; Lilly Continues Gemzar Fight

Executive Summary

Sanofi-Aventis reduces Eloxatin competition: Sanofi-Aventis settled Eloxatin (oxaliplatin) patent infringement suits against Teva, Sandoz and Fresenius Kabi. Under the terms of the settlement the companies will stop selling their generic versions of the colon cancer drug on June 30 and resume marketing under a license on Aug. 9, 2012. The other terms of the settlement are confidential. Eloxatin's compound patent has expired but other patents cover the drug through 2016. As a result of generic competition, Sanofi's U.S. sales of Eloxatin fell from $1.4 billion in 2008 to $930 million in 2009. Hospira, Sun and Sun's U.S. subsidiary Caraco also market generic versions of Eloxatin. Sanofi has pending suits against MN Pharmaceuticals, Mayne Pharma and Actavis

You may also be interested in...



Diversification, Not Genzyme, Is The Theme Of Sanofi's Year-End Financial Report

Sanofi's sales declined by 1% in 2010 and net income increased by 2.6%, although €2 billion in sales were lost to generics during the year.

Earnings In Brief

Acorda's Ampyra sales best Wall Street expectations: The firm reported $29.7 million worth of Ampyra has shipped to its network of specialty pharmacies, which is how Acorda books sales, during its first full quarter of sales. FDA approved Ampyra (dalfampridine) in January to improve walking ability in multiple sclerosis patients, and Acorda launched it in March. In its second-quarter earnings call, Acorda said 4,200 doctors have now prescribed the drug. Ampyra's strength helped Acorda beat analyst estimates handily, posting a loss of 18 cents rather than the expected 46 cents. The firm's sales totaled $43.4 million, which also included $13.7 million in gross sales of anti-spasticity drug Zanaflex. The company is looking to in-license a development-stage neurology drug by the end of 2010. A Phase I trial for a remyelination agent, expected to begin this summer, has been delayed due to a vial-filling issue

Earnings In Brief

Acorda's Ampyra sales best Wall Street expectations: The firm reported $29.7 million worth of Ampyra has shipped to its network of specialty pharmacies, which is how Acorda books sales, during its first full quarter of sales. FDA approved Ampyra (dalfampridine) in January to improve walking ability in multiple sclerosis patients, and Acorda launched it in March. In its second-quarter earnings call, Acorda said 4,200 doctors have now prescribed the drug. Ampyra's strength helped Acorda beat analyst estimates handily, posting a loss of 18 cents rather than the expected 46 cents. The firm's sales totaled $43.4 million, which also included $13.7 million in gross sales of anti-spasticity drug Zanaflex. The company is looking to in-license a development-stage neurology drug by the end of 2010. A Phase I trial for a remyelination agent, expected to begin this summer, has been delayed due to a vial-filling issue

Related Content

Topics

UsernamePublicRestriction

Register

PS142970

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel